Sclerosing Cholangitis as ImmuneRelated Adverse Event Caused by Nivolumab and Ipilimumab Therapy - Abstract
Immune checkpoint inhibitors (ICIs) cause several immune-related adverse events (irAEs); however, few studies have described sclerosing cholangitis (SC) and its therapeutics.